Literature DB >> 16959761

REMATCH and beyond: the cost of treating heart failure using an implantable left ventricular assist device.

Walter P Dembitsky1.   

Abstract

Congestive heart failure is an increasingly widespread debilitating fatal condition that generates a high cost to patients, society, and health care systems. Nearly 6.5 million people in Europe and 5 million people in the United States have congestive heart failure. Unlike most cardiovascular diseases in industrialized countries, congestive heart failure is becoming more common. Therapies include medical approaches, implantable assist devices, and cardiac transplantation. Mechanical assistance devices rather than medical therapy offer improvement in quality of life and survival.

Entities:  

Mesh:

Year:  2006        PMID: 16959761     DOI: 10.1177/1089253206291148

Source DB:  PubMed          Journal:  Semin Cardiothorac Vasc Anesth        ISSN: 1089-2532


  3 in total

1.  Design of a pulsatile flow facility to evaluate thrombogenic potential of implantable cardiac devices.

Authors:  Sivakkumar Arjunon; Pablo Hidalgo Ardana; Neelakantan Saikrishnan; Shalv Madhani; Brent Foster; Ari Glezer; Ajit P Yoganathan
Journal:  J Biomech Eng       Date:  2015-02-11       Impact factor: 2.097

Review 2.  A ventricular assist device as a bridge to recovery, decision making, or transplantation in patients with advanced cardiac failure.

Authors:  Siyamek Neragi-Miandoab
Journal:  Surg Today       Date:  2012-07-20       Impact factor: 2.549

3.  Orthotopic heart transplant versus left ventricular assist device: a national comparison of cost and survival.

Authors:  Daniel P Mulloy; Castigliano M Bhamidipati; Matthew L Stone; Gorav Ailawadi; Irving L Kron; John A Kern
Journal:  J Thorac Cardiovasc Surg       Date:  2012-12-13       Impact factor: 5.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.